TIROSINT-SOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TIROSINT-SOL (TIROSINT-SOL).
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
| Metabolism | Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine. |
| Excretion | Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces. |
| Half-life | Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks. |
| Protein binding | >99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin. |
| Volume of Distribution | 0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors. |
| Bioavailability | Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets. |
| Onset of Action | Oral: 3–5 days for measurable metabolic effects; full effect may take 2–3 weeks. |
| Duration of Action | Single oral dose: metabolic effects persist for 2–4 weeks; clinical duration corresponds to half-life and tissue stores. |
| Molecular Weight | 776.87 |
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR < 60 mL/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired. |
| Pediatric use | Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4. |
| Geriatric use | Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 mIU/L due to higher risk of cardiac effects. |
| 1st trimester | Levothyroxine is indicated for maternal hypothyroidism; insufficient thyroid hormone in pregnancy is harmful to fetus. Dose may need increase. No teratogenicity in humans. |
| 2nd trimester | Continued use essential; monitor thyroid function and adjust dose to maintain euthyroid state. |
| 3rd trimester | Continue as needed; dose adjustments may be required postpartum. |
Clinical note
Comprehensive clinical and safety monograph for TIROSINT-SOL (TIROSINT-SOL).
| Placental transfer | Limited placental transfer; levothyroxine crosses placenta minimally. Endogenous thyroid hormone transfer is regulated. |
| Breastfeeding | Levothyroxine is excreted into breast milk in very low amounts; not expected to cause adverse effects in nursing infants. Monitor infant thyroid function if high maternal doses used. |
■ FDA Black Box Warning
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
| Serious Effects |
Untreated thyrotoxicosisUncorrected adrenal insufficiencyHypersensitivity to levothyroxine or any excipient
| Precautions | Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications. |
| Food/Dietary | Absorption of levothyroxine is reduced by high-fiber foods, soy products, grapefruit juice, and caffeine. Iron, calcium, aluminum- or magnesium-containing antacids, and bile acid sequestrants also inhibit absorption. Separate ingestion of TIROSINT-SOL from these substances by at least 4 hours. |
Loading safety data…
| Lactation Rating |
| L1 (Safe) |
| Teratogenic Risk | Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins. |
| Fetal Monitoring | Monitor maternal serum TSH and free T4 every 4-6 weeks during pregnancy, and after any dose adjustment. Maintain TSH within trimester-specific reference ranges (first trimester 0.1-2.5 mIU/L, second 0.2-3.0, third 0.2-3.5). Assess maternal thyroid function postpartum if dose was increased during pregnancy. For fetus, assess growth and development via ultrasound; guideline recommends TSH screening at birth if maternal hypothyroidism is treated. |
| Fertility Effects | Untreated hypothyroidism can cause anovulatory cycles, menstrual irregularities, and infertility. Achieving euthyroid state with levothyroxine restores normal ovulatory function and improves fertility outcomes. No direct adverse effects on gametes or embryo. Continue therapy during assisted reproductive technology cycles. |
| Clinical Pearls | TIROSINT-SOL is a liquid formulation of levothyroxine sodium used for patients who cannot swallow tablets, have GI absorption issues, or require precise dosing. Administer on an empty stomach (30–60 minutes before breakfast) with water only. Avoid administration with iron, calcium, or antacids within 4 hours. Monitor TSH 4–6 weeks after dose changes. Use caution in patients with cardiovascular disease; start with low doses. T4 replacement may unmask adrenal insufficiency in panhypopituitarism—screen with ACTH stimulation test if suspected. |
| Patient Advice | Take TIROSINT-SOL exactly as prescribed, usually once daily on an empty stomach, at least 30–60 minutes before eating or drinking anything except water. · Do not mix the solution with any other liquids or foods; only use the provided oral syringe for accurate dosing. · Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding, as dose adjustments may be needed. · Do not stop taking this medication without consulting your doctor, even if you feel well; thyroid hormone replacement is usually lifelong. · Store the solution in the refrigerator (36°F to 46°F) and use within 60 days after first opening; do not freeze. |